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Breast cancer type 2, early onset susceptibility gene (BRCA2) is a major component
of the homologous recombination DNA repair pathway. It acts as a tumor suppressor
whose function is often lost in cancers. Patients with specific mutations in the BRCA2
gene often display discrete clinical, histopathological, and molecular features. However,
a subset of sporadic cancers has wild type BRCA2 and display defects in the homology-
directed repair pathway, which is the hallmark of ‘BRCAness.’ The mechanisms by
which BRCAness arises are not well understood but post-transcriptional regulation of
BRCA2 gene expression by microRNAs (miRNAs) may contribute to this phenotype.
Here, we examine the post-transcriptional effects that some members of the six-
miRNA cluster known as the miR-17/92 cluster have on the abundance of BRCA2’s
messenger RNA (mRNA) and protein. We discuss two interactions involving the miR-
19a and miR-19b members of the cluster and the 3′UTR of BRCA2’s mRNA. We
investigated these miRNA:mRNA interactions in 15 cell lines derived from pancreatic,
breast, colon, and kidney tissue. We show that over-expression of these two miRNAs
results in a concomitant decrease of BRCA2’s mRNA and protein expression in a
subset of the tested cell lines. Additionally, using luciferase reporter assays we identified
direct interactions between miR-19a/miR-19b and a miRNA response element (MRE)
in BRCA2’s 3′UTR. Our results suggest that BRCA2 is subject to a complex post-
transcriptional regulatory program that has specific dependencies on the genetic and
phenotypic background of cell types.
Keywords: BRCA2, cancer, DNA repair, microRNA, the miR-17/92 cluster, miR-19a, miR-19b, post-transcriptional
regulation
Abbreviations: 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region; ACTB, actin-beta; Ago, argonaute protein;
Ago CLIP-seq, argonaute cross-linking immunoprecipitation and deep sequencing; ATCC, American type culture collection;
BRCA1, breast cancer 1, early onset gene; BRCA2, breast cancer 2, early onset gene; C. elegans, Caenorhabditis elegans;
cDNA, complementary DNA; CDS, coding sequence; ceRNAs, competitive endogenous RNAs; DNA, deoxyribonucleic acid;
DDR, DNA damage response; DSDB, double strand DNA breaks; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
HDR, homology-directed repair; miRNA, microRNA; mRNA, messenger ribonucleic acid; MRE, miRNA response element;
MUT, mutant type; ncRNA, non-coding RNA; nts, nucleotides; PARP, poly (ADP ribose) polymerase; qRT-PCR, quantitative
reverse-transcription polymerase chain reaction; RNA, ribonucleic acid; RNA-seq, RNA sequencing; SE, standard error; SDS-
PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TNBC, triple negative breast cancer; UTR, untranslated
region; WB, western blot; WT, wild type.
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INTRODUCTION
The DNA repair pathway functions to correct potential damages
to the chromosomes that occur during DNA replication or upon
insult by environmental factors. Alterations of this pathway
have been associated with many different diseases, most notably
cancers (Gavande et al., 2016). Among the genes participating
in this pathway, BRCA2 is one of the best-studied (Cleton-
Jansen et al., 1995; Goldgar et al., 1995; Wooster et al., 1995;
Venkitaraman, 2002; Wooster and Weber, 2003; Turner et al.,
2004; Prakash et al., 2015). BRCA2 is essential for the support
of chromosomal integrity, and functions as an effector of HDR
of DSDB and stalled replication forks (Moynahan et al., 2001;
Lomonosov et al., 2003; Schlacher et al., 2011). BRCA2 functions
during embryogenesis and normal development and is expressed
in all tissues with some of the highest levels found in breast and
thymus (Roy et al., 2012).
Human BRCA2 has two known protein-coding transcripts
with lengths of 11,986 and 10,984 nucleotides (nts), respectively.
Both mRNAs code for a large protein (384,225 Da) that comprises
3,418 amino acids (Venkitaraman, 2002; Roy et al., 2012).
BRCA2 does not show substantial sequence similarities to other
proteins and has been co-evolving with BRCA1 (Lou et al., 2014).
The amino acid sequence of BRCA2 shows poor conservation
among vertebrates (Prakash et al., 2015) with 59.2% identity
between human and mouse (Connor et al., 1997) and 37%
identity between human and chicken (Warren et al., 2002). By
comparison, other tumor suppressors such as MSH, XPA, and
TP53 are much better conserved with the human and mouse
sequences exhibiting 92, 86, and 77% similarity, respectively
(Jasin, 2002).
In cancers, BRCA2 functions as a tumor suppressor gene
(Bieche and Lidereau, 1995; Collins et al., 1995). Similarly to
BRCA1, BRCA2 is haploinsufficient: mutation of one copy of
BRCA2 results in hereditary autosomal-dominant breast and
ovarian cancer syndrome (Roy et al., 2012). Also BRCA2 germline
mutations increase one’s risk to develop pancreatic, stomach,
laryngeal, fallopian tube, or other cancers. BRCA2 germline
mutations are the most frequent genetic alteration in familial
pancreatic cancer and occur in 5–20% of the patients (Murphy
et al., 2002; Hahn et al., 2003; Couch et al., 2007; Dagan, 2008;
Ferrone et al., 2009; Ghiorzo et al., 2012; Luo et al., 2015; Zhen
et al., 2015). Additionally, BRCA2 mutations occur in 3.6–10% of
all sporadic pancreatic cancers (Goggins et al., 1996; Ozcelik et al.,
1997; Figer et al., 2001; Ferrone et al., 2009; Lucas et al., 2013; Luo
et al., 2015). Recent therapeutic strategies using platinum salts
and poly (ADP-ribose) polymerase (PARP) inhibitors exploit the
presence of BRCA1/BRCA2 mutations in the synthetic lethality
concept (Bryant et al., 2005; Farmer et al., 2005; Helleday et al.,
2005).
Tumors with BRCA1/2 mutations exhibit specific phenotypes.
Recent evidence has revealed that some sporadic forms of cancers
exhibit similar molecular, histological, and clinical phenotypes
even in the absence of BRCA1/2 mutations, a defect known as
‘BRCAness,’ whose mechanism is not well understood (Turner
et al., 2004; Lord and Ashworth, 2016). As much as 25% of
sporadic breast and ovarian cancers exhibit this phenotype
(Cancer Genome Atlas Research Network, 2011, Banerji et al.,
2012; Cancer Genome Atlas Network, 2012; Stephens et al., 2012;
Patch et al., 2015). Additionally, lung, prostate, and pancreatic
cancer also exhibit BRCAness phenotype (Couch et al., 2007;
Beltran et al., 2013; Holter et al., 2015; Lord and Ashworth, 2016).
The phenotype renders tumors sensitive to platinum salts and
PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005; Helleday
et al., 2005).
MiRNAs are short (∼22 nt in length) ncRNAs that act
as post-transcriptional regulators and are typically derived
from endogenous hairpin-like transcripts (Bartel, 2004, 2009).
MiRNAs regulate the abundance of both protein-coding genes
and ncRNAs by inhibiting protein translation or through mRNA
degradation (He and Hannon, 2004; Filipowicz et al., 2008). Since
the discovery of the first animal miRNA, lin-4, in C. elegans
(Ambros, 1989; Ruvkun and Giusto, 1989), miRNAs have been
characterized in numerous animal species and plants, and
several viruses (Kozomara and Griffiths-Jones, 2014). The public
repository of miRNA sequences known as miRBase (Kozomara
and Griffiths-Jones, 2014) lists 2,588 human mature miRNAs in
its latest release. However, in a recent report, by analyzing data
from only 13 human tissues, we reported an additional 3,707
human miRNAs, which suggests that the eventual number of
human miRNAs is likely to be higher (Londin et al., 2015).
MiRNAs are involved in the regulation of many different
biological processes, including proliferation, apoptosis, DNA
repair, and many others. Their aberrant expression has been
associated many diseases and disorders including cancer (Calin
et al., 2004; Meng et al., 2007; Peng et al., 2011; Fang et al., 2012;
Huang et al., 2014; Misso et al., 2014), cardiovascular (Corsten
et al., 2010; Fichtlscherer et al., 2010; Zampetaki and Mayr, 2012;
Philippen et al., 2015), immune-related (Stanczyk et al., 2008;
Junker et al., 2009; Lofgren et al., 2012; Nielsen et al., 2012;
Liu et al., 2014; Yang et al., 2014), neurodegenerative conditions
(Nunez-Iglesias et al., 2010; Margis et al., 2011; Martins et al.,
2011; Femminella et al., 2015) and other diseases (Starczynowski
et al., 2010; Wu et al., 2010; Brest et al., 2011). MiRNAs are
also involved in the DNA repair pathway: for example, miR-24,
miR-421, and miR-21 modulate the expression of multiple DDR
genes such as H2AX, ATM, and CDC25A, respectively (Hu and
Gatti, 2011); miR-1245, miR-1255b, and miR-193b∗ were shown
to target BRCA2 (Song et al., 2012; Choi et al., 2014); and, we
recently reported that the miR-15/107 group of miRNAs targets
BRCA1 (Quann et al., 2015).
A miRNA exerts its function by targeting sites within
transcripts that are known as ‘miRNA response elements’ or
MREs. The interaction of a miRNA with an MRE occurs in a
sequence-depended manner (Lee et al., 1993; Reinhart et al., 2000;
Bartel, 2004; Fabian et al., 2010; Xia et al., 2012). According to
the canonical model, (1) MREs are located within the 3′UTR of
the targeted mRNA transcript (Wightman et al., 1993); (2) within
the ‘seed’ region, which spans positions 2–7 inclusive from the
miRNA’s 5′ end, bases form Watson–Crick pairs (Reinhart et al.,
2000; Bartel, 2004); and, (3) miRNA targets tend to be conserved
across species (Friedman et al., 2009). However, previous work
by others and us has been generating evidence in support of an
expanded model of miRNA targeting where one or more of these
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three ‘rules’ are not satisfied (Wightman et al., 1993; Ha et al.,
1996; Easow et al., 2007; Baek et al., 2008; Selbach et al., 2008; Tay
et al., 2008; Lal et al., 2009; Hafner et al., 2010; Thomas et al., 2010;
Zisoulis et al., 2010; Chi et al., 2012; Skalsky et al., 2012; Zhou and
Rigoutsos, 2014; Quann et al., 2015).
The miR-17/92 cluster, also known as ‘oncomiR-1’ (He et al.,
2005), comprises six miRNAs (miR-17, miR-18a, miR-19a, miR-
19b-1, miR-20a, and miR-92) and is an important regulator in
health (Marcelis et al., 2008; Ventura et al., 2008; Carraro et al.,
2009; Grillari et al., 2010; Jiang et al., 2011) and disease (Tsitsiou
and Lindsay, 2009; Yu et al., 2010; Morimura et al., 2011; Tsuchida
et al., 2011; Angerstein et al., 2012; Diehl et al., 2012; Heegaard
et al., 2012; Schonrock et al., 2012; Diaz-Beya et al., 2013). For
recent reviews, see (Mogilyansky and Rigoutsos, 2013; Fuziwara
and Kimura, 2015; Khuu et al., 2016).
In this work, we combined computational miRNA target
predictions of candidate miRNAs that potentially interact with
BRCA2’s mRNA with experimental work. Specifically, we focused
our analysis on the role of two miRNAs, miR-19a and miR-19b,
the members of the miR-17/92 cluster, and their interactions with
BRCA2 for the following reasons. First, these two members of the
miR-17/92 cluster are known to be sufficient for recapitulating
the oncogenicity of the whole cluster (Mu et al., 2009; Olive et al.,
2009; van Haaften and Agami, 2010). Second, miR-19a and miR-
19b are over-expressed in several cancers, including pancreatic
and breast cancers (Mogilyansky and Rigoutsos, 2013). Third,
in the primary screening of the miR-17/92 cluster members and
putative five MREs, miR-19a and miR-19b show the greatest
statistically significant decrease of the luciferase activity. Fourth,
RNA-seq datasets (Londin et al., 2015) show that miR-19a and
miR-19b increase from normal pancreas to early stage pancreatic
cancer and then increase again from early stage to late stage of
the disease. Fifth, RNA-seq datasets (Londin et al., 2015) show
that miR-19a and miR-19b are increased in pancreatic cancer
cell lines compared to the normal epithelial pancreatic cell line
hTERT-HPNE. All of the above provide the rationale to focus on
the miR-19a and miR-19b for this study. We examined the effects
of these two miRNAs on BRCA2 mRNA and protein expression
and present our findings in a variety of cancerous and non-
cancerous model cell lines from pancreatic, breast, kidney and
colon tissues.
MATERIALS AND METHODS
Identification of miRNA Targets
MiRNA targets were computationally predicted using RNA22
(Miranda et al., 2006). Candidate MREs were permitted along
the entire length of BRCA2’s mRNA, i.e., in the 5′UTR,
the amino acid coding sequence (CDS), and in the 3′UTR.
Additionally, putative miRNA:mRNA interactions were allowed
to include non-Watson–Crick base pairings and/or bulges in
the seed region of the corresponding heteroduplexes. The
candidate interactions were filtered further and only those with
experimental support from our mining of public and in-house
datasets generated through crosslinking followed by Argonaute
(Ago) immunoprecipitation and deep sequencing (Ago CLIP-seq;
Yano et al., 2010; Kishore et al., 2011; Leung et al., 2011; Loeb
et al., 2012) were kept (Clark et al., 2014).
Cell Lines
Human cell lines hTERT-HPNE, PL45, MIA PaCa-2, BxPC-
3, PANC-1, AsPC-1, Capan-2, MDA-MB-231, MDA-MB-468,
BT-20, MCF7, MCF-10A, and HCT 116 were obtained from
the American Type Culture Collection (ATCC; Manassas, VA,
USA). 239T cells were obtained from Thermo Fisher Scientific
(Pittsburg, PA, USA). The PL-5 cells were a kind gift from Dr.
Jonathan Brody (Thomas Jefferson University, Philadelphia, PA,
USA). All cell lines were cultured using standard techniques and
conditions recommended by the manufacturer’s protocols.
Reagents
MiRNA precursors to hsa-miR-19a-3p (miR-19a), hsa-miR-19b-
3p (miR-19b), and anti-miRs, anti-miR-19a-3p (anti-miR-19a),
anti-miR-19b-3p (anti-miR-19b), negative controls for miR-
and anti-miR precursors, and positive control BRCA2-specific
siRNA (siBRCA2) were obtained from Ambion/Thermo Fisher
Scientific.
Quantitation of Expression
Cells were seeded in 6-well plates with 50% confluency and
transfected 24 h later with 50 nM of miRNA- or anti-miRNA
precursors according to manufacturer’s instructions. Cells were
also transfected with the relevant negative and positive controls in
parallel. At 48 h post-transfection, total RNA was extracted from
cells using TRIzol (Thermo Fisher Scientific). cDNA synthesis
was performed with SuperScript III Reverse Transcriptase
(Invitrogen/Thermo Fisher Scientific) with presence of Random
Primers (Invitrogen/Thermo Fisher Scientific). BRCA2 qRT-PCR
was performed with SYBR Select Master Mix (Thermo Fisher
Scientific) and 25 ng of cDNA templates. Primer sequences
used for qRT-PCR are shown in Supplementary Table S1. The
human GAPDH RNA was amplified in parallel as an internal
control. Samples were amplified on a StepOnePlus Real-Time
PCR System (Applied Biosystems/Thermo Fisher Scientific).
Relative gene expression levels were calculated by the 11CT
method with normalization to GAPDH. All data for qRT-
PCR assays are expressed as mean ± SE with a sample size
of n = 3 for each group. Statistical analyses between test
and control group were performed with unpaired two-tailed
Student’s t-test assuming equal variances. P-values ≤ 0.05 were
considered statistically significant. ∗P ≤ 0.05, ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
For WB, cells were harvested 72 h post-transfection and
re-suspended in Pierce RIPA lysis buffer (Thermo Fisher
Scientific) containing complete protease inhibitors cocktail
(Roche, Basel, Switzerland). Cells were then incubated on
ice for 30 min with brief vortexing. The cellular debris was
pelletized by centrifugation at 10,000 × g for 10 min and
protein concentrations determined using Pierce BCA Protein
Assay Kit (Thermo Fisher Scientific). Equal amount of lysates
(10 µg) were separated on 6–12% sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) at 120 V. Electrophoretic
transfer to nitrocellulose membranes (GE Healthcare, Little
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Chalfont, Buckinghamshire, UK) was performed overnight at
4◦C at 25 V. All membranes were blocked in 5% non-fat dry
milk (Thermo Fisher Scientific) before overnight incubation
with primary antibody in 1% Tris-buffered saline Tween-20
(TBST; Thermo Fisher Scientific) with 5% bovine serum albumin
(Sigma–Aldrich, St. Louis, MO, USA) at the manufacturer’s
recommended dilution at −2 to −8◦C. The membranes were
washed and incubated with appropriate secondary antibody
in 1% TBST (Thermo Fisher Scientific) with 5% non-fat dry
milk for 1 h at room temperature. The signal was developed
using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific) and detected using ImageQuant
LAS4000 Imaging system (GE Healthcare). The primary
antibodies include: anti-BRCA2 1:2,000 dilution (ab123491;
Abcam, Cambridge, MA, USA), β-actin antibody 1:1,000
dilution (3700S; Cell Signaling Technologies, Denver, MA,
USA). The secondary antibodies include: HRP-linked anti-mouse
IgG 1:2,000 dilution (7076, Cell Signaling Technologies) and
HRP-linked anti-rabbit IgG antibody 1:2,000 dilutions (7074;
Cell Signaling Technologies). Band intensities were measured
using ImageJ with normalization to actin-beta (ACTB) and
appropriate controls Scramble miR/Scramble anti-miR. All data
for WB are expressed as mean ± SE with a sample size
of n = 3 for each group. Statistical analyses between test
and control group were performed with unpaired two-tailed
Student’s t-test assuming equal variances. P-values ≤ 0.05 were
considered statistically significant. ∗P ≤ 0.05, ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
Luciferase Assays
Cells were seeded in 96-well plates with 50% confluency and
transfected 24 h later with 50 nM of miRNA precursors
and BRCA2 MREs according to manufacturer’s instructions.
Cells were also transfected with appropriate negative and
positive controls in parallel. Oligonucleotide sequences (100 nts)
corresponding to the WT predicted target sites/MREs, WT
BRCA2 MRE-4, mutated predicted binding site (MUT BRCA2
MRE-4) or fully complementary to miR-19a or miR-19b (As-
miR-19a, As-miR-19b) were synthesized and augmented to
include XhoI and NotI restriction sites (Invitrogen/Thermo
Fisher Scientific). Scrambled Vector (100 nts) was designed
and used as negative control in parallel (Supplementary
Table S2). Oligonucleotides were annealed, purified, double-
digested with the XhoI and NotI restriction enzymes (New
England Biolabs, Ipswich, MA, USA) and cloned into the 3′UTR
of Renilla luciferase within the psiCHECK-2 Dual-Luciferase
Reporter vector (Promega, Madison, WI, USA) using standard
techniques. 48 h after cell transfection with the appropriate
psiCHECK-2 vector carrying the cloned sequence of interest,
miRNA precursors and controls Renilla and Firefly luciferase
levels were measured with the Dual-Luciferase Reporter Assay
System (Promega) according to the manufacturer’s instructions.
Luciferase activity for each sample was measured using a
Multi-mode microplate reader Synergy 2 (BioTeck Instruments,
Winooski, VT, USA). For the presented analyses, target
Renilla luciferase activity was normalized to control Firefly
luciferase activity. All data for luciferase assays are expressed
as mean ± SE with a sample size of n = 3 for each
group. Statistical analyses between test and control group were
performed with unpaired two-tailed Student’s t-test assuming
equal variances. P-values ≤ 0.05 were considered statistically
significant. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001.
RESULTS
MiRNAs from the miR-17/92 Cluster are
Predicted to Target BRCA2 mRNA
To date, only a few miRNAs have been shown to regulate
BRCA2 (Song et al., 2012; Choi et al., 2014), and none of them
are members of the miR-17/92 cluster. Using a combination
of computational (RNA22) and experimental approaches (Ago
CLIP-seq) we selected BRCA2 as one of the targets of the
miR-17/92 cluster and identified candidate binding sites within
BRCA2 mRNA (Figure 1; Supplementary Table S3). Our analysis
allowed for mRNA sites that are beyond the 3′UTR and could
contain bulges and non-Watson–Crick base pairs in the seed
region of the heteroduplex. We identified five sites that were
located within the CDS and 3′UTR and screened them using
luciferase assays (Figure 2). Out of the five putative miRNA
binding sites/MREs targeted by four members of the miR-17/92
cluster, WT BRCA2 MRE-4 responded to transfections with miR-
19a and miR-19b exhibiting a concomitant statistically significant
decrease of luciferase activity (P < 0.001). This is the MRE on
which we focused our studies. Interestingly, miR-19a and miR-
19b are ubiquitously expressed in all tissues and have previously
been reported to have oncogenic properties (Mu et al., 2009; Olive
et al., 2009; van Haaften and Agami, 2010); this in turn suggests
a possible role for these two miRNAs in post-transcriptionally
regulating BRCA2 mRNA.
MiR-19a and miR-19b Decrease BRCA2
mRNA Levels
We hypothesized that over-expression of miR-19a/miR-19b will
decrease endogenous BRCA2 mRNA levels. Using a panel of
15 cell lines with WT BRCA2 we examined BRCA2 mRNA
expression following over-expression of each of these two
miRNAs. Generally, kidney and pancreatic cell lines showed
greater BRCA2 mRNA suppression compared to breast and
colon cell lines. In particular, 293T, hTERT-HPNE, PL45, and
Capan-2 cells had the greatest response to both miR-19a
and miR-19b treatments ranging from 20 to 80% decrease
of BRCA2 mRNA levels (P < 0.05; Figure 3A). In contrast,
BRCA2 mRNA level did not change in PANC-1 cells. In MIA
PaCa-2 and BxPC-3, BRCA2 mRNA levels varied only in
response to miR-19a treatment, but not to miR-19b. Interestingly,
BRCA2 mRNA levels did not change in response to miR-
19a or miR-19b in the breast cancer cell lines MDA-MB-231,
MCF7, and BT-20 (Supplementary Figure S1A). In addition,
BRCA2 mRNA levels increased in MCF-10A following miR-
19a treatment by as much as 2.1x. Also BRCA2 mRNA levels
increased in MDA-MB-468 and HCT 116 following miR-19b
treatment. Anti-miR-19a and anti-miR-19b generally abrogated
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FIGURE 1 | Predicted miRNAs response elements (MREs) within BRCA2 for the miR-17/92 cluster. (A) Schematic representation of BRCA2 transcripts
showing the putative miR-17/92 cluster’s MREs in the CDS and the 3′UTR predicted by the RNA22 algorithm and cross-filtered using Ago CLIP-seq-derived
heteroduplex architectures. The highlighted MRE for miR-19a/miR-19b was studied in detail. (B) The predicted miRNA:mRNA heteroduplexes. Underlined
sequences in red are where binding between the miRNA ‘seed’ and the MRE occurs. Purple letter (C or U) is a single different nucleotide between miR-19a and
miR-19b. Blue solid lines are Watson–Crick base pairings and dotted blue lines are non-Watson–Crick base pairings, e.g., G:U wobbles.
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FIGURE 2 | Primary screening of five putative miR-17/92 MREs by luciferase assays. The putative wild type BRCA2 miRNA response elements (WT BRCA2
MREs) were cloned into a luciferase reporter vector psiCHECK-2. Renilla luciferase activity was normalized to Firefly luciferase activity. All shown data are
mean ± Standard error. P-values ≤ 0.05 were considered statistically significant. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001 compared to Scramble miR/Scrambled Vector by
two-tailed Student’s t-test assuming equal variances, n = 3.
the effects of miR-19a and miR-19b on BRCA2 mRNA except
for MIA PaCa-2 and PL45 cells treated with anti-miR-19a,
and MDA-MB-468 and HCT 116 cells treated with anti-miR-
19b (Figure 3B; Supplementary Figure S1B). Furthermore, a
siBRCA2 decreased BRCA2 mRNAs levels in all cell lines
(P < 0.01) except MDA-MB-468. The summary of the qRT-PCR
results in all 15 cell lines are presented in Supplementary Table S4.
Taken together these results suggest a possible regulation of
BRCA2 mRNA by miR-19a and miR-19b that is dependent
upon the cell type, with the greatest effect in pancreatic cancer
cells.
Over-expression of miR-19a and
miR-19b Leads to Decrease of BRCA2
Protein Levels
The above results revealed a specific regulation for BRCA2 mRNA
by miR-19a and miR-19b in six cell lines (293T, hTERT-HPNE,
PL45, Capan-2, MIA PACa-2, and BxPC-3), out of the 15 cell
lines that we examined. To determine if the decrease in mRNA
abundance led to similar decreases in BRCA2 protein levels,
we performed BRCA2 WB in those cell lines, under the same
conditions, and observed an appreciable decrease of BRCA2
protein levels following treatment with miR-19a and miR-19b in
two of the cell lines: hTERT-HPNE and PL45 with band intensity
decrease by as much as 74% (P < 0.001; Figure 4). In 293T and
PANC-1 cells BRCA2 protein levels decreased only in response to
miR-19a or miR-19b treatment between 53% (P < 0.05) and 76%
(P< 0.01). BRCA2 protein levels were not affected by miR-19a or
miR-19b in the BxPC-3 and MIA PaCa-2 pancreatic cancer cell
lines. Capan-2 cells showed very low basal level of BRCA2 (result
not shown), which could affect result interpretation and were
excluded from the subsequent experiments. Over-expression of
anti-miR-19a/anti-miR-19b precursors rescues BRCA2 protein
levels in 293T, hTERT-HPNE and PL45 by as much as 6.51-fold
(P < 0.01). Over-expression of anti-miR-19b precursors rescues
BRCA2 protein levels in PANC-1 as well BRCA2 protein level
is significantly increased with treatment of anti-miR-19b in MIA
PACa-2 cell line by as much as 1.5-fold (P< 0.01). As anticipated,
siBRCA2 consistently decreased BRCA2 protein levels between
25 and 97% in all cell lines (Figure 4). We found that the
results for qRT-PCR and WB showing BRCA2 levels change with
over-expression of miR-19a and miR-19b are mostly concordant
(Supplementary Table S5). These results suggest that miR-19a and
miR-19b inhibit the translation of BRCA2 mRNA in a subset of
the examined cell lines.
MiR-19a and miR-19b Directly Target an
MRE in BRCA2’s 3′UTR in Several Cell
Lines
Our results show that miR-19a and miR-19b affect BRCA2 mRNA
and protein abundances in specific cell contexts. To determine
whether these effects are due to direct interactions between the
miRNAs and BRCA2, we performed Dual-Luciferase Reporter
Assays. We used constructs that contained the predicted WT
target site WT BRCA2 MRE-4, mutant binding site with three
consecutive point mutations MUT BRCA2 MRE-4, and ones that
are fully complementary to miR-19a (As-miR-19a) and miR-19b
(As-miR-19b; Supplementary Table S2). These constructs were
cloned into the 3′UTR of the luciferase gene of the reporter
expression vector and tested in a set of six cell lines: 293T, hTERT-
HPNE, PL45, Capan-2, BxPC-3, and PANC-1. Treatments
with miR-19a/miR-19b precursors and WT BRCA2 MRE-4
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FIGURE 3 | MiR-19a and miR-19b over-expression affects the endogenous levels of BRCA2 mRNA in kidney and pancreatic cell lines. (A) Ectopic
over-expression of miR-19a/miR-19b decreases BRCA2 mRNA levels in a first group of nine cell lines. (B) Ectopic over-expression of anti-miR-19a/anti-miR-19b
increases BRCA2 mRNA levels in several of the nine cell lines. Cells were transfected with miRNA/anti-miRNA precursors and at 48 h post-transfection the levels of
BRCA2 mRNA were measured using qRT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control. All shown data are
mean ± Standard error. P-values ≤ 0.05 were considered statistically significant. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 compared to Scramble miR/Scramble
anti-miR by two-tailed Student’s t-test assuming equal variances, n = 3.
demonstrated significant decrease in luciferase activity, by as
much as ∼25% (P < 0.001) in 293T, PL45, BxPC-3, and PANC-1
cell lines (Figures 5 and 6). Interestingly, in hTERT-HPNE we
observed a decrease in luciferase activity only with miR-19a and
WT BRCA2 MRE-4 treatments, while in Capan-2 we did not
observe a statistically significant reduction of luciferase activity
with miR-19a/miR-19b treatments (Figure 6). MiR-19a/miR-
19b co-transfected with a reporter expression vector containing
As-miR-19a/As-miR-19b decreased luciferase levels even further
compared to control co-transfection: decreases as much as 50%
(P < 0.001) in 293T and as much as 80–90% (P < 0.001) in
other cell lines (Figure 5). Point mutations in the miR-19a/miR-
19b binding site abolished the inhibitory effect on luciferase
activity. This effect was observed for a mutant construct with
three consecutive point mutations compared to the WT site.
The greatest effect of increased luciferase activity compared to
scramble control miRNA precursor was observed in Capan-2
cells: treatment with miR-19a co-transfected with MUT BRCA2
MRE-4 lead to a ∼20% increase (P < 0.05) of luciferase activity
(Figure 6). These observations show that miR-19a and miR-19b
directly interact with BRCA2, and that this effect is happening in a
cell type specific manner similarly to what we showed previously
for BRCA1 (Quann et al., 2015).
DISCUSSION
BRCA2 is an important gene in the DNA repair pathway
whose altered function has been associated to many different
cancers (Couch et al., 2007; Cancer Genome Atlas Research
Network, 2011, Cancer Genome Atlas Network, 2012; Roy
et al., 2012; Beltran et al., 2013; Holter et al., 2015; Norris
et al., 2015; Patch et al., 2015). Also, it is known that BRCA2
dysregulation can result in a BRCAness phenotype (Lord and
Ashworth, 2016). While the roles of germline and somatic
mutations in the gene’s activities have been well characterized,
very little is known about its post-transcriptional regulation
program (Song et al., 2012; Choi et al., 2014). MiR-19a and
miR-19b are ubiquitously expressed and have been shown to
be sufficient in capturing the miR-17/92 cluster’s oncogenic
properties (Mu et al., 2009; Olive et al., 2009; van Haaften and
Agami, 2010). In the above, we examined the interplay between
these two competing molecular classes. Specifically, we studied
the miRNA-mediated post-transcriptional regulation of BRCA2
and determined that miR-19a and miR-19b directly interact with
an MRE in BRCA2’s 3′UTR. Several lines of evidence show that
these interactions result in a decrease of BRCA2 mRNA and
protein abundance.
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FIGURE 4 | Ectopic over-expression of miR-19a and miR-19b affects the endogenous levels of BRCA2 protein in kidney and pancreatic cell lines.
Ectopic over-expression of miR-19a/miR-19b decreases BRCA2 protein levels in a cell-dependent manner. Cells were transfected with miRNA/anti-miRNA
precursors and at 72 h post-transfection BRCA2 protein was detected by western blot (WB). Band intensities were quantitated using ImageJ. Actin-beta (ACTB) was
used as internal control. All shown data are mean ± Standard error. P-values ≤ 0.05 were considered statistically significant. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001
compared to Scramble miR/Scramble anti-miR by two-tailed Student’s t-test assuming equal variances, n = 3.
MiR-19a and miR-19b are known to play key roles in the
oncogenic properties of the miR-17/92 cluster and are often
up-regulated in a wide variety of cancers, including breast
and pancreatic cancers (Volinia et al., 2006, 2010; Szafranska
et al., 2007; Mogilyansky and Rigoutsos, 2013). Many of the
experimentally validated targets (e.g., PTEN, STAT2, TSP-1, and
CTGF) of these two miRNAs are involved in such processes
as cell death, proliferation, immune response and angiogenesis
(Ventura et al., 2008; Dews et al., 2010; Mogilyansky and
Rigoutsos, 2013). However, to date only a few miRNAs have
been shown to target genes in the DNA repair pathway,
and in particular BRCA2 (Hu and Gatti, 2011; Wan et al.,
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FIGURE 5 | MiR-19a and miR-19b directly target BRCA2 within the 3′UTR in several cell lines. The putative wild type BRCA2 MRE (WT BRCA2 MRE-4) was
cloned into a luciferase reporter vector psiCHECK-2 along with mutant BRCA2 MRE (MUT BRCA2 MRE-4) and fully complementary sequences for miR-19a
(As-miR-19a) and miR-19b (As-miR-19b). (A) 293T, (B) hTERT-HPNE, and (C) PL45. Underlined sequences in red are where binding between the miRNA ‘seed’ and
the MRE occurs. The blue letters are mutated nts in the MRE. Renilla luciferase activity was normalized to Firefly luciferase activity. All shown data are
mean ± Standard error. P-values ≤ 0.05 were considered statistically significant. ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 compared to Scramble miR/Scrambled Vector by
two-tailed Student’s t-test assuming equal variances, n = 3.
Frontiers in Genetics | www.frontiersin.org 9 August 2016 | Volume 7 | Article 143
fgene-07-00143 August 29, 2016 Time: 12:37 # 10
Mogilyansky et al. BRCA2 Regulation by miR-19a/19b
FIGURE 6 | MiR-19a and miR-19b directly target BRCA2 within the 3′UTR in additional cell lines. The putative wild type BRCA2 MRE (WT BRCA2 MRE-4)
was cloned into a luciferase reporter vector psiCHEK-2 along with a mutant BRCA2 MRE (MUT BRCA2 MRE-4) and fully complementary sequences for miR-19a
(As-miR-19a) and miR-19b (As-miR-19b) (A) BxPC-3, (B) PANC-1, and (C) Capan-2. Underlined sequences in red are where binding between the miRNA ‘seed’
and the MRE occurs. The blue letters are mutated nts in the MRE. Renilla luciferase activity was normalized to Firefly luciferase activity. All shown data are
mean ± Standard error. P-values ≤ 0.05 were considered statistically significant. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 compared to Scramble miR/Scrambled
Vector by two-tailed Student’s t-test assuming equal variances, n = 3.
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2011; Chowdhury et al., 2013). The ubiquitous expression of
BRCA2 and its long 3′UTR (∼1,500 nts) make the study of
its miRNA post-transcriptional regulation a uniquely attractive
and challenging task. Over-expression of miR-19a/miR-19b often
correlates with loss of BRCA1/BRCA2 protein expression in
breast, ovarian cancer, pancreatic, and other cancers (King, 2004;
Malone et al., 2009; Li et al., 2010), which raised the possibility
that miR-19a/miR-19b could be involved in the regulation of
BRCA2; however, we are not aware of any earlier reports that
demonstrated direct targeting of BRCA2 mRNA by members of
the miR-17/92 cluster and regulation of its mRNA and protein
abundance.
Our studies present several lines of evidence that support the
direct targeting of BRCA2 by miR-19a and miR-19b. First, over-
expression of each of the two miRNAs results in a decrease of
BRCA2 mRNA and protein levels in a cell-dependent manner.
Second, by using a luciferase construct containing the miR-
19a/miR-19b MRE we show a decrease in luciferase expression
and prove miR-19a/miR-19b and BRCA2 MRE direct physical
interactions.
We tested miR-19a/miR-19b:BRCA2 interactions in 15 cell
lines derived from pancreatic, breast, colon cancers, and
kidney. All tested cell lines are WT for BRCA2, but have
mutations in other genes that are implicated in BRCAness.
For example, AsPC-1, BxPC-3, MIA PaCa-2, MDA-MB-231,
MDA-MB-468, and BT-20 have TP53 mutations. MDA-MB-
468 has a PTEN mutation, which has been correlated with
HDR defects, but whose exact mechanism is not clear. In
addition, a subset of the cell lines has mutations in genes
that were previously linked to a cancer phenotype, including
KRAS (in MDA-MB-231, MIA PaCa-2, Capan-2, AsPC-1, and
HCT 116) and CDKN2A (in MCF7, MDA-MB-231, and HCT
116).
Recent reports claim that the BRCAness phenotype occurs
not only in a large percentage of breast and ovarian cancers,
but also in a wide spectrum of cancers, including prostate and
pancreatic cancers (Couch et al., 2007; Cancer Genome Atlas
Research Network, 2011, Banerji et al., 2012; Cancer Genome
Atlas Network, 2012; Stephens et al., 2012; Beltran et al., 2013;
Holter et al., 2015; Patch et al., 2015). The BRCAness phenotype
could be explained in part by miRNA (dys-) regulation of
BRCA2. Previous studies linked BRCA2’s post-transcriptional
regulation by miRNAs to breast and ovarian cancer cell lines
(Song et al., 2012; Choi et al., 2014). In this study, we extended
the analysis to include kidney, pancreatic, and colon cell
lines.
We identified an MRE for miR-19a/miR-19b that is located
in the 3′UTR of BRCA2’s two protein-coding transcripts. The
predicted heteroduplexes with miR-19a or miR-19b comprise
classical Watson–Crick base pairing in the seed region of
the respective miRNA. However, the identified MRE is not
conserved across species e.g., it is present in chimpanzee (Pan
troglodytes), but absent in mouse (Musculus), chicken (Gallus
gallus domesticus) and zebrafish (Danio rerio). Of note, our group
recently reported the regulation of another DNA repair gene,
BRCA1, by the miR-15/107 group of miRNAs, through an MRE
located within the mRNA’s CDS; that interaction supported the
expanded model of miRNA targeting (Quann et al., 2015).
We studied the impact of ectopic over-expression of miR-
19a/miR-19b on the levels of BRCA2 mRNA and protein in
kidney, pancreatic, breast, and colon cells. Studies have shown
that triple negative breast cancers (TNBCs) have enriched
HDR defects, namely defective RAD51 formation, and increased
chromosomal aberrations (Banerji et al., 2012; Cancer Genome
Atlas Network, 2012; Stephens et al., 2012). However, our
analyses do not support the possibility of BRCA2 down-
regulation by miR-19a or miR-19b in the three TNBC cell
lines that we tested, namely MDA-MB-231, MDA-MB-468, and
BT-20. Quite paradoxically, we observed the opposite in the
MDA-MB-468 cell line: BRCA2 mRNA levels increased following
treatment with miR-19b. Possible explanations include increased
stabilization of the mRNA leading to increased transcription
(Li et al., 2006; Miranda et al., 2006; Huang et al., 2012),
the presence of indirect effects on BRCA2 through, e.g.,
competitive endogenous RNAs (ceRNAs) interactions (Karreth
et al., 2011; Tay et al., 2011) or, a direct interaction with
BRCA2’s promoter region (Place et al., 2008). Another factor
could be the difference in basal levels of BRCA2 mRNA
expression. In fact, MDA-MB-468 cells had the highest level
of BRCA2 expression among breast cancer cells and did not
respond to siBRCA2, even though the other cell lines did
respond.
Pancreatic cells (hTERT-HPNE, PL45, Capan-2, and
BxPC-3) showed, generally, a decrease of BRCA2 levels upon
treatment with miRNAs. Nonetheless, we observed considerable
differences among pancreatic cell lines with regard to changes of
BRCA2 mRNA and protein levels following miR-19a/miR-19b
treatments. In particular, in BxPC-3 cells, miR-19a treatment led
to a decrease of BRCA2 mRNA but no concomitant change of
BRCA2 protein level whereas miR-19b treatment did not change
mRNA levels yet led to a large increase of protein abundance.
Several previous studies described similar behavior between
mRNA and protein levels in the BRCA2 context (Song et al.,
2012; Choi et al., 2014) and elsewhere (Schwanhausser et al.,
2011; Vogel and Marcotte, 2012; Londin et al., 2014). The two
known BRCA2 mRNAs are rather long (Venkitaraman, 2002;
Roy et al., 2012): thus, it is conceivable that cooperative action
by more than one miRNAs operating through multiple MREs
is needed in order to appreciably decrease BRCA2 mRNA
levels.
We notice that most of the studied pancreatic cell lines (PL45,
MIA PaCa-2, Capan-2, BxPC-3, PANC-1, and PL-5) derived from
the primary tumor with exception of AsPC-1. However, most of
the studied breast cell lines (MDA-MB-231, MDA-MB-468, and
MCF7) derived from metastatic sites with the exception of BT-20,
which derived from a primary site. Indeed, we observed that miR-
19a/miR-19b were able to decrease BRCA2 mRNA levels from
the group of pancreatic cells derived from a primary site, but we
didn’t see the same effect in breast cells derived from a primary
site.
We presented evidence of direct interactions between miR-
19a/miR-19b and the BRCA2 MREs, which were cloned in a
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luciferase reporter vector. The luciferase assay shows consistent
and robust decrease of luciferase activity following treatment with
miR-19a and miR-19b in several cell lines (293T, hTERT-HPNE,
PL45, BxPC-3, and PANC-1).
The main finding of this work is the discovery of a link
between miR-19a and miR-19b, two members of the oncogenic
miR-17/92 cluster, and the post-transcriptional regulation of
BRCA2, one of the regulators of the DDR pathway. The
functional implications of this link are not known and need to
be investigated. In particular, it will be important to determine
whether these interactions lead to defective HDR, a hallmark
of BRCAness. The results would improve our understanding of
BRCA2’s post-transcriptional regulation by miRNAs and could
prove helpful in improving clinical management of the disease
and designing improved therapies that target the DNA repair
defects. For example, in the presence of BRCAness, a tumor
with a miRNA down-regulated BRCA2 can have similar clinical
features as a tumor with BRCA2 germline mutations: in such a
case, patients from either group would have similar prognosis
and may require similar adjuvant or neoadjuvant therapies. Also
tumors with miRNA-down-regulated BRCA2 could be more
sensitive to platinum salts and PARP inhibitors, which would
help expand the treatment options for patients with sporadic
cancers.
Members of the miR-17/92 cluster have been shown to
target a number of important genes, but its involvement
in DNA repair awaits further investigation. Given the wide
array of cancers in which miR-19a and miR-19b are dys-
regulated such studies are warranted. Lastly, it is important
to remain aware of the cell-type dependence that our
experiments uncovered and which mirror findings we reported
recently for BRCA1 (Quann et al., 2015). This dependence
suggests a very rich molecular context in which regulation
of BRCA2 takes place and whose details await discovery and
characterization.
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